Clinical-stage biotech Sareum Holdings plc (LSE:SAR) has announced a proposed share fundraise under AIM's new Capital Access Window, pausing trading in its shares while the raise is carried out. The size, price and structure of the fundraise have not been disclosed.
What was announced
Sareum Holdings plc (LSE:SAR) said on 8 October 2026 that it intends to raise new Share Capital using the Capital Access Window, a mechanism introduced through updates to the AIM Rules for Companies announced in August 2026. The company referred to the transaction as the "Proposed Fundraise". The announcement was marked as containing inside information under the UK Market Abuse Regulation.
The Capital Access Window took effect at 7.30am on 8 October 2026. Sareum described it as a "voluntary temporary pause in the trading of the Company's shares on AIM", intended to allow it to reach a broader range of investors and to provide pricing stability during the fundraising process. The pause will remain in place until a further announcement reports the results of the Proposed Fundraise.
A separate notice published the same day confirmed the position on the market side. It stated that trading in Sareum's ordinary shares of £0.0125 each (ISIN GB00BMC3RJ87) was temporarily suspended on AIM from 7.30am on 8 October 2026, at the company's request, under a Capital Access Window pending an announcement. This is a pause linked to the fundraise rather than a suspension for any other reason given in the notice.
What is and is not known
The stated purpose of the raise is to fund Sareum's lead clinical programme, SDC-1801, towards its "next key clinical inflection point". The announcement does not define what that inflection point is, what clinical work it would involve or when the company expects to reach it.
No amount to be raised, issue price, number of shares, investor type or structure was disclosed. The company said the announcement is not an offer of securities and that the material terms will be set out in later announcements. It is therefore not yet possible to say how large the raise will be relative to the company's existing share capital, whether it will include a retail element, or whether directors will take part.
SDC-1801 and the company
SDC-1801 is a small molecule that inhibits two enzymes, TYK2 and JAK1, at the same time. Sareum describes it as a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.
Sareum is a clinical-stage biotechnology company based in Cambridge, UK, developing next-generation kinase inhibitors for autoimmune disease and cancer, with a focus on small molecules that modify the activity of the JAK kinase family. Its pipeline also includes SDC-1802, a TYK2/JAK1 inhibitor with potential use in certain blood cancers, and a preclinical programme developing TYK2/JAK1 inhibitors for neuroinflammatory conditions such as multiple sclerosis and Parkinson's disease. The company also holds the licence for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor aimed at cancer cell replication and DNA damage repair.
Strand Hanson is nominated adviser, and Singer Capital Markets and Oberon Capital act as joint corporate brokers. Stephen Parker is Executive Chairman.
What to watch next
The key next step is the results announcement for the Proposed Fundraise, which should set out the amount raised, the issue price, the number of new shares and any discount to the previous share price. That announcement will also bring the Capital Access Window to an end, after which trading in the shares is expected to resume. Further detail on how the proceeds will be applied to SDC-1801, and what the company regards as its next clinical inflection point, would also be relevant.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...